Point-Counterpoint: Should Clinical Microbiology Laboratories Report Vancomycin MICs?


Journal

Journal of clinical microbiology
ISSN: 1098-660X
Titre abrégé: J Clin Microbiol
Pays: United States
ID NLM: 7505564

Informations de publication

Date de publication:
19 03 2021
Historique:
pubmed: 5 2 2021
medline: 9 7 2021
entrez: 4 2 2021
Statut: epublish

Résumé

INTRODUCTIONWith numerous reported challenges to reporting MICs for vancomycin, clinical laboratories are attempting to identify accurate methods for MIC testing. However, the issues of poor reproducibility, accuracy, and clinical utility remain a challenge. In this Point-Counterpoint, Dr. Sara Revolinski discusses the pros of reporting MICs for vancomycin, while Dr. Christopher Doern argues for the use of caution.

Identifiants

pubmed: 33536296
pii: JCM.00239-21
doi: 10.1128/JCM.00239-21
pmc: PMC8092730
pii:
doi:

Substances chimiques

Anti-Bacterial Agents 0
Vancomycin 6Q205EH1VU

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2021 American Society for Microbiology.

Références

Diagn Microbiol Infect Dis. 2017 Jul;88(3):259-263
pubmed: 28449844
Ther Drug Monit. 2015 Oct;37(5):619-25
pubmed: 26378371
Antibiotics (Basel). 2016 Sep 27;5(4):
pubmed: 27690120
Clin Infect Dis. 2012 Mar;54(6):755-71
pubmed: 22302374
Antimicrob Agents Chemother. 2008 Sep;52(9):3315-20
pubmed: 18591266
J Infect Dis. 2009 Nov 1;200(9):1355-66
pubmed: 19811099
Clin Ther. 2013 Jun;35(6):772-9
pubmed: 23795575
Antimicrob Agents Chemother. 2014;58(1):309-16
pubmed: 24165176
Clin Infect Dis. 2014 Sep 1;59(5):666-75
pubmed: 24867791
Am J Health Syst Pharm. 2009 Jan 1;66(1):82-98
pubmed: 19106348
Antimicrob Agents Chemother. 2017 Nov 22;61(12):
pubmed: 28923869
Antimicrob Agents Chemother. 2017 May 24;61(6):
pubmed: 28373187
Am J Health Syst Pharm. 2018 Dec 15;75(24):1986-1995
pubmed: 30333114
JAMA. 2014 Oct 15;312(15):1552-64
pubmed: 25321910
Clin Infect Dis. 2012 Jan 1;54(1):51-8
pubmed: 22109947
Clin Pharmacokinet. 2004;43(13):925-42
pubmed: 15509186
Pharmacotherapy. 2019 Apr;39(4):433-442
pubmed: 30739349
Clin Infect Dis. 2009 Aug 1;49(3):325-7
pubmed: 19569969
Int J Infect Dis. 2017 Apr;57:27-31
pubmed: 28131729
J Antimicrob Chemother. 2008 Dec;62(6):1413-21
pubmed: 18782781
Antimicrob Agents Chemother. 2016 Aug 22;60(9):5276-84
pubmed: 27324762
Clin Infect Dis. 2014 Jun;58(11):1533-9
pubmed: 24642554
J Clin Microbiol. 2014 Nov;52(11):3898-905
pubmed: 25143569
Antimicrob Agents Chemother. 2007 Jul;51(7):2582-6
pubmed: 17452488
Clin Infect Dis. 2010 Sep 15;51(6):641-50
pubmed: 20695801
J Infect Dis. 2011 Aug 1;204(3):340-7
pubmed: 21742831
Antimicrob Agents Chemother. 2019 Apr 25;63(5):
pubmed: 30858203
Antimicrob Agents Chemother. 2012 Feb;56(2):634-8
pubmed: 22123681
PLoS One. 2016 Jan 05;11(1):e0146224
pubmed: 26731739
Antimicrob Agents Chemother. 2008 Dec;52(12):4528
pubmed: 18838599
Clin Infect Dis. 2008 Jan 15;46(2):193-200
pubmed: 18171250
Eur J Clin Microbiol Infect Dis. 2010 Feb;29(2):171-80
pubmed: 19946789
Open Forum Infect Dis. 2019 Mar 15;6(Suppl 1):S47-S53
pubmed: 30895214
Pharmacotherapy. 2009 Nov;29(11):1275-9
pubmed: 19873687
Clin Infect Dis. 2011 Apr 15;52(8):969-74
pubmed: 21460308
J Antimicrob Chemother. 2016 Dec;71(12):3575-3584
pubmed: 27585969
Pharmacotherapy. 2013 Jan;33(1):3-10
pubmed: 23307539
J Antimicrob Chemother. 2014 Jan;69(1):211-8
pubmed: 23997017
Antimicrob Agents Chemother. 2015;59(6):2978-85
pubmed: 25753631
Antimicrob Agents Chemother. 2013 Apr;57(4):1654-63
pubmed: 23335735
Antimicrob Agents Chemother. 2018 Jan 25;62(2):
pubmed: 29203493
J Clin Microbiol. 2013 Jul;51(7):2077-81
pubmed: 23596249
Clin Infect Dis. 2011 Apr 15;52(8):975-81
pubmed: 21460309
Int J Antimicrob Agents. 2008 Nov;32(5):378-85
pubmed: 18701261
Intensive Care Med. 2011 Apr;37(4):639-47
pubmed: 21253703
Antimicrob Agents Chemother. 2016 Sep 23;60(10):5841-8
pubmed: 27431221
Diagn Microbiol Infect Dis. 2010 Jul;67(3):228-33
pubmed: 20542203
Clin Infect Dis. 2013 Jun;56(11):1562-9
pubmed: 23449272
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9
pubmed: 16323118
Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S3-4
pubmed: 16323117
Int J Infect Dis. 2013 Feb;17(2):e93-e100
pubmed: 23089040
Int J Antimicrob Agents. 2012 Dec;40(6):496-509
pubmed: 23068600
Clin Infect Dis. 2011 Feb 1;52(3):e18-55
pubmed: 21208910

Auteurs

Sara L Revolinski (SL)

Medical College of Wisconsin, School of Pharmacy, Milwaukee, Wisconsin, USA cdoern@mcvh-vcu.edu srevolin@mcw.edu.

Christopher D Doern (CD)

Virginia Commonwealth University Health System, Richmond, Virginia, USA cdoern@mcvh-vcu.edu srevolin@mcw.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH